LONDON, Jan 30 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its long-term efficacy ...

Of course, like all wardrobe basics, there are several tiers of quality and prices for sweatshirts. You have your more affordable crewnecks, staples like Champion, H&M, and Russell, which fans ...

Mexico's President Claudia Sheinbaum said on Sunday that reason should prevail a day after her government and the U.S. announced tariffs against one another, raising her fist in the air as she ...

The pair were wearing matching navy blue hoodies adorned with a white lightning bolt which appear to be from fashion brand Aviator Nation. Archie looked so grown up wearing a pair of smart jeans ...

If you buy something, we may earn an affiliate commission. For decades, it seemed like the only hoodies worth wearing were of the pullover variety. No longer: the best zip-up hoodies for men are ...

The collection includes shirts, hoodies, hats and more. You can get free U.S. shipping with orders of $24 or more with code 24SHIP. Ohio State will play Notre Dame in the College Football Playoff ...

The stock is down about 40% from a record in June, with a chunk of the drop coming after disappointing results for a separate drug called CagriSema in December. The experimental CagriSema shot ...

The collection oozes luxury, featuring a signature suede jacket with premium zippers, delicate stitching, and functional pockets for versatile style. Its artisanal dyeing and suede goat leather ...

The stock is down about 40% from a record in June, with a chunk of the drop coming after disappointing results for a separate drug called CagriSema in December. The experimental CagriSema shot missed ...

The stock is down about 40% from a record in June, with a chunk of the drop coming after disappointing results for a separate drug called CagriSema in December.

Just over a month after its CagriSema readout disappointed analysts, Novo Nordisk released promising data for its obesity drug amycretin. The Danish pharmaceutical giant ended off the week on a high ...

Novo Nordisk is “well placed” to continue to benefit from the high demand for GLP-1 medications in the near-term, and while the CagriSema Phase 3 data in obesity was disappointing, it is still ...